Ieq Capital LLC Invests $5.26 Million in Twist Bioscience Corporation $TWST

Key Points

• Ieq Capital LLC acquired 51,109 shares of Twist Bioscience valued at approximately $5.26 million, while several other institutional investors—including BlackRock, ARK Investment Management, and Millennium Management—also increased or initiated positions.
• Twist Bioscience reported quarterly revenue of $118.38 million, up 23.2% year over year, but missed the consensus EPS estimate with a loss of $0.56 per share. Analysts maintain a “Moderate Buy” consensus rating, with an average price target of $98.30.
• The stock opened at $145.59, near its 12-month high of $145.93, despite ongoing losses and negative profitability metrics. Insiders sold approximately $17.7 million worth of shares over the past 90 days, including significant sales by CEO Emily Leproust.

Ieq Capital LLC purchased a new position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 51,109 shares of the company's stock, valued at approximately $5,258,000. Ieq Capital LLC owned approximately 0.08% of Twist Bioscience at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. purchased a new position in Twist Bioscience in the second quarter worth about $600,191,000. William Blair Investment Management LLC grew its holdings in shares of Twist Bioscience by 43.7% during the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company's stock valued at $188,874,000 after buying an additional 1,812,146 shares during the last quarter. EdgePoint Investment Group Inc. increased its position in shares of Twist Bioscience by 31.7% during the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company's stock valued at $170,590,000 after acquiring an additional 1,295,672 shares in the last quarter. Millennium Management LLC increased its position in shares of Twist Bioscience by 151.5% during the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company's stock valued at $50,479,000 after acquiring an additional 1,080,722 shares in the last quarter. Finally, ARK Investment Management LLC raised its holdings in Twist Bioscience by 12.4% in the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company's stock worth $239,787,000 after acquiring an additional 832,687 shares during the last quarter.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $145.59 on Monday. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $145.93. The firm has a market capitalization of $9.13 billion, a price-to-earnings ratio of -65.58 and a beta of 2.14. The firm has a 50 day moving average of $100.69 and a 200 day moving average of $70.50. The company has a current ratio of 2.67, a quick ratio of 2.38 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analysts' expectations of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience's revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.33 EPS. As a group, research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Activity

In other Twist Bioscience news, insider Dennis Cho sold 14,205 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the sale, the insider owned 105,141 shares in the company, valued at approximately $9,436,404.75. This represents a 11.90% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Emily M. Leproust sold 113,318 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.16, for a total value of $14,182,880.88. Following the completion of the sale, the chief executive officer owned 818,938 shares of the company's stock, valued at $102,498,280.08. The trade was a 12.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 151,529 shares of company stock valued at $17,708,772 over the last 90 days. Company insiders own 3.08% of the company's stock.

Analysts Set New Price Targets

TWST has been the topic of several analyst reports. Barclays upped their price objective on Twist Bioscience from $65.00 to $95.00 and gave the company an "overweight" rating in a research report on Wednesday, June 24th. TD Cowen restated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Guggenheim upped their price target on Twist Bioscience from $60.00 to $107.00 and gave the company a "buy" rating in a report on Monday, June 29th. Robert W. Baird increased their price objective on Twist Bioscience from $113.00 to $115.00 and gave the company an "outperform" rating in a research report on Tuesday, August 4th. Finally, Canaccord Genuity Group lifted their price objective on Twist Bioscience from $90.00 to $120.00 and gave the stock a "buy" rating in a report on Tuesday, July 14th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Twist Bioscience has a consensus rating of "Moderate Buy" and a consensus price target of $98.30.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source